Compare YQ & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YQ | ALLR |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.7M | 25.6M |
| IPO Year | 2020 | 2021 |
| Metric | YQ | ALLR |
|---|---|---|
| Price | $2.29 | $1.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 4.7K | ★ 227.3K |
| Earning Date | 06-09-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $320,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.70 | $0.77 |
| 52 Week High | $6.45 | $2.35 |
| Indicator | YQ | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 43.26 | 45.55 |
| Support Level | $1.95 | $1.29 |
| Resistance Level | $2.62 | $1.80 |
| Average True Range (ATR) | 0.15 | 0.14 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 11.51 | 31.91 |
17 Education & Technology Group Inc is engaged in providing education and education technology services in the People's Republic of China (PRC) with a focus on the Teaching and Learning SaaS offerings. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.